Input:
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic
 profile of HB002.1T in combination with different chemotherapy regimens administered to
 patients with advanced solid tumors.
 ;
 ;
 Inclusion Criteria:
 1. 18 years≤Age≤75 years
 2. Histologically or cytologically confirmed advanced malignant solid tumor , including
 gastric cancer, ovarian cancer, cervical cancer, head and neck cancer, lung cancer,
 biliary tract tumor, pancreatic cancer, bladder cancer and nasopharyngeal carcinoma
 (not limited to the above tumor types) . And be suitable for the treatment of HB0021.T
 combined with 3 different chemotherapy regimen assessed by the investigators.
 3. No prior radiotherapy, chemotherapy, targeted therapy, endocrine therapy or
 immunotherapy within 4 weeks before the first administration of HB002.1T. And no
 traditional herb medicines for anti-tumor within 2 weeks .
 4. No prior antiangiogenic therapy such as bevacizumab, ramucirumab, apatinib or
 regofinib, et al.
 5. At least one measurable tumor lesion as per RECIST criteria v1.1
 6. ECOG performance status of 0 or 1
 7. Life expectancy of at least 12 weeks
 8. Meet following organ functions:
 1. Absolute neutrophil count ≥2.0 x 10^9/L(no Recombinant human granulocyte colony
 stimulating factor support therapy with 14 days)
 2. Hemoglobin ≥100g/L(no blood transfusion or erythropoietin support treatment was
 received within 14 days)
 3. Platelet count ≥100×10^9/L (No Recombinant human thrombopoietin and other
 supportive therapies within 14 days prior to screening phase)
 4. Serum creatinine≤1.5×ULN or creatinine clearance of≥60ml/min (based on the
 Cockcroft Gault formula).
 5. Serum total bilirubin≤1.5×ULN.
 6. ALT and AST ≤2.5×ULN, with the following exceptions: Patients with liver
 metastases assessed by investigators: AST and/or ALT≤5×ULN
 7. Blood potassium≥3.0 mmol/L, blood calcium≥2.0 mmol/L
 8. Prothrombin time (PT)≤1.2×ULN, partial prothrombin kinase time (APTT)≤1.2×ULN
 9. Urine protein < 1+showed by urine test paper, or urine protein <1g for 24 hours
 9. Previous treatment toxicity returned to grade 1 as per NCI CTCAE 5.0, with the
 following exceptions :Hair loss or other with no safety risk judged by investigators.
 10. Subjects of childbearing potential must be willing to take effective contraceptive
 measures throughout the study and for 3 months after the last dose of HB002.1T.And
 females must have a negative pregnancy test during the screening period .
 11. Ability to understand the patient information and informed consent form and signed and
 dated written informed consent form.
 Exclusion Criteria:
 - Patients who meet any of the following criteria will be excluded from study entry:
 1. Confirmed active CNS metastasis and /or cancerous meningitis; For patients with
 stable clinical symptoms for brain metastasis for more than 3months can be
 enrolled.
 2. Positive test for hepatitis B, hepatitis C, or HIV at screening.
 3. History of organ transplantationHistory of severe allergy or known severe
 allergic reactions (greater than grade 3 in CTCAE V5.0) to macromolecular protein
 preparations / monoclonal antibodies and any components of the test drug;
 4. Have received other clinical trial drugs within 4 weeks before the first
 treatment of HB002.1T;
 5. Have undergone major surgery within 4 weeks prior to screening;
 6. Have undergone minor surgical procedures (including catheterization, except for
 PICC) within 2 days prior to screening;
 7. Systolic blood pressure≥140mmHg and/or diastolic blood pressure≥90mmHg after
 antihypertensive treatment (one antihypertensive drug is allowed in the baseline
 period, and the compound preparation is recognized as two);
 8. An active infection requiring antibiotics treatment during the screening period,
 or an unexplained fever > 38.5 °C occurs before the first dose;
 9. Hemoptysis within 4 weeks before screening (defined as coughing with ≥1 teaspoon
 of blood), but do not rule out cough only with sputum or small blood clot;
 10. Suffering from the following serious complications:
 1. Prior arterial thromboembolic events, venous thrombosis great than grade 3
 or higher in NCI CTCAE5.0
 2. Previous or current persistent bleeding or coagulation disorders
 3. Dominant jaundice and/or coagulopathy caused by abnormal liver function
 4. Chronic Obstructive Pulmonary Disease (COPD) or other respiratory illness
 requiring hospitalization within 4 weeks prior to screening;
 5. History of abdominal hernia, gastrointestinal perforation abscess or acute
 bleeding within 6 months prior to screening;
 6. Esophageal varices, unhealed ulcer, wounds or fractures within 6 months
 prior to screening;
 7. Active cardiovascular diseases including but not limited to transient
 ischemic attack (TIA), cerebral vascular accident (CVA), transmural
 Myocardial infarction), transmural myocardial infarction, myocardial
 infarction (MI), hypertensive crisis or encephalopathy within 6 months prior
 to screening;
 8. Gastrointestinal disorders or conditions that may cause gastrointestinal
 bleeding or perforation (e.g., duodenal ulcer, intestinal obstruction, acute
 Crohn's disease, ulcerative colitis, massive gastrectomy and small bowel
 resection). Patients with chronic Crohn's disease and ulcerative colitis
 (except those with total colectomy and rectal resection) should be excluded
 even in the inactive stage
 9. Patients with hereditary nonpolyposis colorectal cancer or familial
 adenomatous polyposis syndrome;
 10. Previous intestinal perforation and intestinal fistula, still not recover
 after surgical treatment
 11. Absorption of oral drug will be significantly affected assessed by
 investigators (Cohort1 only)
 11. Subjects who are in use of warfarin, heparin , aspirin (>325 mg/day) or other
 drugs known to inhibit platelet function within 10 days prior to the first study
 treatment;
 12. Subjects receiving dipyridamole, ticlopidine, clopidogrel or cilostazol
 treatment;
 13. Subjects with a clear history of neurological or dysfunction, such as poor
 adherence to epilepsy;
 14. Pregnant or nursing women;
 15. Any other reasons assessed by the investigator that are not suitable for
 participation in the trial.